478 results on '"Nafteux P"'
Search Results
2. Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma
- Author
-
Tom Vandaele, Jan Van Slambrouck, Patrick Schöffski, Herlinde Dumez, Birgit Weynand, Raf Sciot, Annalisa Barbarossa, An-Lies Provoost, Kristof Van de Voorde, Yves Debaveye, Sofian Bouneb, Philippe Nafteux, and Laurens J. Ceulemans
- Subjects
Pleural yolk sac tumor ,Pleural synovial sarcoma ,Hyperthermic intrathoracic chemotherapy ,Pleural tumor ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Pleural neoplasms are rare and can be subdivided into pleural metastasis and primary pleural neoplasms. Non-mesothelioma primary pleural neoplasms are a diverse group of extremely rare pathologies. Case presentation In this case series, we describe the presentation and management of two rare primary pleural neoplasms. A first case describes a primary pleural yolk sac tumor treated with neoadjuvant chemotherapy, extended pleurectomy decortication, and hyperthermic intrathoracic chemotherapy. In a second case we describe the management of a primary pleural synovial sarcoma by neoadjuvant chemotherapy and extrapleural pneumonectomy. A complete resection was obtained in both cases and the post-operative course was uncomplicated. No signs of tumor recurrence were noted during follow-up in the first patient. In the second patient a local recurrence was diagnosed 6 months after surgery. Conclusion Neo-adjuvant chemotherapy followed by extensive thoracic surgery, including hyperthermic intrathoracic chemotherapy, is a feasible treatment strategy for non-mesothelioma primary pleural neoplasms, but careful follow-up is required.
- Published
- 2024
- Full Text
- View/download PDF
3. Diagnosis and Management of Esophageal Fistulas After Lung Transplantation: A Case Series
- Author
-
Stijn Vanstraelen, MD, Robin Vos, MD, PhD, Marie Dausy, MD, Jan Van Slambrouck, MD, Cedric Vanluyten, MD, Paul De Leyn, MD, PhD, Willy Coosemans, MD, PhD, Herbert Decaluwé, MD, PhD, Hans Van Veer, MD, Lieven Depypere, MD, PhD, Raf Bisschops, MD, PhD, Ingrid Demedts, MD, PhD, Michael P. Casaer, MD, PhD, Yves Debaveye, MD, PhD, Greet De Vlieger, MD, PhD, Laurent Godinas, MD, PhD, Geert Verleden, MD, PhD, Dirk Van Raemdonck, MD, PhD, Philippe Nafteux, MD, PhD, and Laurens J. Ceulemans, MD, PhD
- Subjects
Surgery ,RD1-811 - Abstract
Background. Lung transplantations are highly complex procedures, often conducted in frail patients. Through the addition of immunosuppressants, healing can be compromised, primarily leading to the development of bronchopleural fistulas. Although esophageal fistulas (EFs) after lung transplantation remain rare, they are associated with significant morbidity. We aimed to investigate the clinical presentation, diagnostic approaches, and treatment strategies of EF after lung transplantation. Methods. All patients who developed EF after lung transplantation at the University Hospitals Leuven between January 2019 and March 2022 were retrospectively reviewed and the clinical presentations, diagnostic approaches, and treatment strategies were summarized. Results. Among 212 lung transplantation patients, 5 patients (2.4%) developed EF. Three patients were male and median age was 39 y (range, 34–63). Intraoperative circulatory support was required in 3 patients, with 2 needing continued support postoperatively. Bipolar energy devices were consistently used for mediastinal hemostasis. All EFs were right-sided. Median time to diagnosis was 28 d (range, 12–48) and 80% of EFs presented as recurrent respiratory infections or empyema. Diagnosis was made through computed tomography (n = 3) or esophagogastroscopy (n = 2). Surgical repair with muscle flap covering achieved an 80% success rate. All patients achieved complete resolution, with only 1 patient experiencing a fatal outcome during a complicated EF-related recovery. Conclusion. Although EF after lung transplantation remains rare, vigilance is crucial, particularly in cases of right-sided intrathoracic infection. Moreover, caution must be exercised when applying thermal energy in the mediastinal area to prevent EF development and mitigate the risk of major morbidity. Timely diagnosis and surgical intervention can yield favorable outcomes.
- Published
- 2024
- Full Text
- View/download PDF
4. ASO Visual Abstract: Major Intraoperative Complications During Minimally Invasive Esophagectomy
- Author
-
Söderström, H., Moons, J., Nafteux, P., Uzun, E., Grimminger, P., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., Nilsson, M., Hayami, M., Degisors, S., Piessen, G., Vanommeslaeghe, H., Van Daele, E., Cheong, E., Gutschow, Ch. A., Vetter, D., Schuring, N., Gisbertz, S. S., and Räsänen, J.
- Published
- 2023
- Full Text
- View/download PDF
5. A Population-Based Study Using Belgian Cancer Registry Data Supports Centralization of Esophageal Cancer Surgery in Belgium
- Author
-
van Walle, Lien, Silversmit, Geert, Depypere, Lieven, Nafteux, Philippe, Van Veer, Hans, Van Daele, Elke, Deswysen, Yannick, Xicluna, Jérôme, Debucquoy, Annelies, Van Eycken, Liesbet, and Haustermans, Karin
- Published
- 2023
- Full Text
- View/download PDF
6. Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Disseminated Thymoma: A Systematic Literature Review
- Author
-
Vandaele, Tom, Van Slambrouck, Jan, Proesmans, Viktor, Clement, Paul, Lambrecht, Maarten, Nafteux, Philippe, Van Raemdonck, Dirk, and Ceulemans, Laurens J.
- Published
- 2023
- Full Text
- View/download PDF
7. Pleural decortication and hyperthermic intrathoracic chemotherapy for pseudomyxoma
- Author
-
Viktor Proesmans, Tom Vandaele, Jan Van Slambrouck, Albert Wolthuis, André D´Hoore, Jeroen Dekervel, Eric Van Cutsem, Raphaëla Dresen, Gert De Hertogh, Karlien Degezelle, Dirk Van Raemdonck, Philippe Nafteux, and Laurens J. Ceulemans
- Subjects
HITHOC ,pleural decortication ,pseudomyxoma peritonei ,Medical technology ,R855-855.5 - Abstract
Aim: Pleural dissemination of pseudomyxoma peritonei (PMP) is an extremely rare diagnosis, for which no standard therapy is available.Methods: We describe the successful treatment of a 67-year-old male diagnosed with left-sided intrapleural dissemination of PMP (low-grade appendiceal mucinous neoplasm), 2 years after treatment of abdominal PMP with cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy. Treatment consisted of extended pleural decortication (ePD) and oxaliplatin-based hyperthermic intrathoracic chemotherapy (HITHOC). The patient is doing well without complications or signs of recurrence, 26 months after thoracic surgery.Conclusion: ePD in combination with HITHOC is a valuable treatment for thoracic PMP.
- Published
- 2022
- Full Text
- View/download PDF
8. ASO Visual Abstract: Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Disseminated Thymoma—A Systematic Literature Review
- Author
-
Vandaele, Tom, Van Slambrouck, Jan, Proesmans, Viktor, Clement, Paul, Lambrecht, Maarten, Nafteux, Philippe, Van Raemdonck, Dirk, and Ceulemans, Laurens J.
- Published
- 2023
- Full Text
- View/download PDF
9. Is Re-introducing Major Open and Minimally Invasive Surgery during COVID-19 Safe for Patients and Healthcare Workers? An International, Multi-centre Cohort Study in the Field of Oesophago-gastric Surgery
- Author
-
Alasmar, Mohamed, Kausar, Afsana, Borgstein, Alexander Berend-Jan, Moons, Johnny, Doran, Sophie, de Pascale, Stefano, Restrepo, Rafael, Verrengia, Apollonia, Alloggio, Mariella, Delgado, Ana Moro, Kumar, Sacheen, del Val, Ismael Díez, Giocapuzzi, Simone, Baiocchi, Gian Luca, de Vega Irañeta, Marta, Salcedo, Gabriel, Vorwald, Peter, Fumagalli Romario, Uberto, Nafteux, Philippe, Gisbertz, Suzanne, Chaudry, Mohammed Asif, and Alkhaffaf, Bilal
- Published
- 2021
- Full Text
- View/download PDF
10. Safety of Esophageal Cancer Surgery During the First Wave of the COVID-19 Pandemic in Europe: A Multicenter Study
- Author
-
Borgstein, Alexander B. J., Brunner, Stefanie, Hayami, Masaru, Moons, Johnny, Fuchs, Hans, Eshuis, Wietse J., Gisbertz, Suzanne S., Bruns, Christiane J., Nafteux, Philippe, Nilsson, Magnus, Schröder, Wolfgang, and van Berge Henegouwen, Mark I.
- Published
- 2021
- Full Text
- View/download PDF
11. Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648
- Author
-
Mortensen, H.R., primary, Populaire, P., additional, Hoffmann, L., additional, Moeller, D.S., additional, Appelt, A., additional, Nafteux, P., additional, Muijs, C.T., additional, Grau, C., additional, Hawkins, M.A., additional, Troost, E.G.C., additional, Defraene, G., additional, Canters, R., additional, Clarke, C.S., additional, Weber, D.C., additional, Korevaar, E.W., additional, Haustermans, K., additional, Nordsmark, M., additional, Gebski, Val, additional, Achiam, M.P., additional, Markar, Sheraz R., additional, Radhakrishna, Ganesh, additional, Berbee, Maaike, additional, Scartoni, Daniele, additional, Orlandi, Ester, additional, Doyen, Jerome, additional, Gregoire, Vincent, additional, Crehange, Gilles, additional, Langendijk, Johannes, additional, Lorgelly, Paula, additional, Blommenstein, Hedwig M., additional, Byskov, Camilla S., additional, Ehmsen, Mai L., additional, Jensen, Maria Fuglsang, additional, Freixas, Gloria Vilches, additional, and Bütoft, Rebecca, additional
- Published
- 2024
- Full Text
- View/download PDF
12. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study
- Author
-
Eliza R. C. Hagens, Mark I. van Berge Henegouwen, Johanna W. van Sandick, Miguel A. Cuesta, Donald L. van der Peet, Joos Heisterkamp, Grard A. P. Nieuwenhuijzen, Camiel Rosman, Joris J. G. Scheepers, Meindert N. Sosef, Richard van Hillegersberg, Sjoerd M. Lagarde, Magnus Nilsson, Jari Räsänen, Philippe Nafteux, Piet Pattyn, Arnulf H. Hölscher, Wolfgang Schröder, Paul M. Schneider, Christophe Mariette, Carlo Castoro, Luigi Bonavina, Riccardo Rosati, Giovanni de Manzoni, Sandro Mattioli, Josep Roig Garcia, Manuel Pera, Michael Griffin, Paul Wilkerson, M. Asif Chaudry, Bruno Sgromo, Olga Tucker, Edward Cheong, Krishna Moorthy, Thomas N. Walsh, John Reynolds, Yuji Tachimori, Haruhiro Inoue, Hisahiro Matsubara, Shin-ichi Kosugi, Haiquan Chen, Simon Y. K. Law, C. S. Pramesh, Shailesh P. Puntambekar, Sudish Murthy, Philip Linden, Wayne L. Hofstetter, Madhan K. Kuppusamy, K. Robert Shen, Gail E. Darling, Flávio D. Sabino, Peter P. Grimminger, Sybren L. Meijer, Jacques J. G. H. M. Bergman, Maarten C. C. M. Hulshof, Hanneke W. M. van Laarhoven, Banafsche Mearadji, Roel J. Bennink, Jouke T. Annema, Marcel G. W. Dijkgraaf, and Suzanne S. Gisbertz
- Subjects
Esophageal cancer ,Lymph node metastases ,Lymphadenectomy ,Esophagectomy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background An important parameter for survival in patients with esophageal carcinoma is lymph node status. The distribution of lymph node metastases depends on tumor characteristics such as tumor location, histology, invasion depth, and on neoadjuvant treatment. The exact distribution is unknown. Neoadjuvant treatment and surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy has not been reached. The aim of this study is to determine the distribution of lymph node metastases in patients with resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed. This can be the foundation for a uniform worldwide staging system and establishment of the optimal surgical strategy for esophageal cancer patients. Methods The TIGER study is an international observational cohort study with 50 participating centers. Patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately individually analyzed by pathological examination. The aim is to include 5000 patients. The primary endpoint is the distribution of lymph node metastases in esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free) survival. Discussion The TIGER study will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed based on these results, such as the optimal radiation field and extent of lymphadenectomy based on the primary tumor characteristics. Trial registration NCT03222895, date of registration: July 19th, 2017.
- Published
- 2019
- Full Text
- View/download PDF
13. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
- Author
-
Lieven Depypere, Melissa Thomas, Johnny Moons, Willy Coosemans, Toni Lerut, Hans Prenen, Karin Haustermans, Hans Van Veer, and Philippe Nafteux
- Subjects
Esophageal neoplasms ,Neoadjuvant therapy ,Treatment outcome ,Adverse effects ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection. Methods We retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002–2010 versus 2011–2015) and histology (adenocarcinoma versus squamous cell carcinoma). Results In 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients’ own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients’ refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months. Conclusions One in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons.
- Published
- 2019
- Full Text
- View/download PDF
14. Corrigendum to 'Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis'
- Author
-
P. Schöffski, I. Timmermans, D. Hompes, M. Stas, Veerle Boecxstaens, F. Sinnaeve, P. De Leyn, W. Coosemans, D. Van Raemdonck, E. Hauben, R. Sciot, P. Clement, O. Bechter, B. Beuselinck, F. J. S. H. Woei-A-Jin, H. Dumez, P. Nafteux, and T. Wessels
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2021
- Full Text
- View/download PDF
15. Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma.
- Author
-
Annouck Philippron, Lieven Depypere, Steffi Oeyen, Bram De Laere, Charlotte Vandeputte, Philippe Nafteux, Katleen De Preter, and Piet Pattyn
- Subjects
Medicine ,Science - Abstract
ObjectiveThe enrichment of circulating tumor cells (CTCs) from blood provides a minimally invasive method for biomarker discovery in cancer. Longitudinal interrogation allows monitoring or prediction of therapy response, detection of minimal residual disease or progression, and determination of prognosis. Despite inherent phenotypic heterogeneity and differences in cell surface marker expression, most CTC isolation technologies typically use positive selection. This necessitates the optimization of marker-independent CTC methods, enabling the capture of heterogenous CTCs. The aim of this report is to compare a size-dependent and a marker-dependent CTC-isolation method, using spiked esophageal cells in healthy donor blood and blood from patients diagnosed with esophageal adenocarcinoma.MethodsUsing esophageal cancer cell lines (OE19 and OE33) spiked into blood of a healthy donor, we investigated tumor cell isolation by Parsortix post cell fixation, immunostaining and transfer to a glass slide, and benchmarked its performance against the CellSearch system. Additionally, we performed DEPArray cell sorting to infer the feasibility to select and isolate cells of interest, aiming towards downstream single-cell molecular characterization in future studies. Finally, we measured CTC prevalence by Parsortix in venous blood samples from patients with various esophageal adenocarcinoma tumor stages.ResultsOE19 and OE33 cells were spiked in healthy donor blood and subsequently processed using CellSearch (n = 16) or Parsortix (n = 16). Upon tumor cell enrichment and enumeration, the recovery rate ranged from 76.3 ± 23.2% to 21.3 ± 9.2% for CellSearch and Parsortix, respectively. Parsortix-enriched and stained cell fractions were successfully transferred to the DEPArray instrument with preservation of cell morphology, allowing isolation of cells of interest. Finally, despite low CTC prevalence and abundance, Parsortix detected traditional CTCs (i.e. cytokeratin+/CD45-) in 8/29 (27.6%) of patients with esophageal adenocarcinoma, of whom 50% had early stage (I-II) disease.ConclusionsWe refined an epitope-independent isolation workflow to study CTCs in patients with esophageal adenocarcinoma. CTC recovery using Parsortix was substantially lower compared to CellSearch when focusing on the traditional CTC phenotype with CD45-negative and cytokeratin-positive staining characteristics. Future research could determine if this method allows downstream molecular interrogation of CTCs to infer new prognostic and predictive biomarkers on a single-cell level.
- Published
- 2021
- Full Text
- View/download PDF
16. Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis
- Author
-
P. Schöffski, I. Timmermans, D. Hompes, M. Stas, F. Sinnaeve, P. De Leyn, W. Coosemans, D. Van Raemdonck, E. Hauben, R. Sciot, P. Clement, O. Bechter, B. Beuselinck, F. J. S. H. Woei-A-Jin, H. Dumez, P. Nafteux, and T. Wessels
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background. Solitary fibrous tumor (SFT) is a rare variant of soft tissue sarcoma (STS). Materials and Methods. We reviewed SFT patients (pts) treated at our institution between 12/1990 and 09/2017. Results. We identified 94 pts with a median follow-up (mFU) of 4.7 years (range: 0.1–21.53). Primary sites were the chest (33%), abdomen (21.3%), brain (12.8%), and extremities (9.6%); 6.4% of pts presented with synchronous metastasis. Median overall survival (mOS) from the first diagnosis was 56.0 months (m) (0.3–258.3). Doege–Potter syndrome was seen in 2.1% of pts. Primary resection was performed in 86 pts (91.5%). Median progression-free survival was 34.1 m (1.0–157.1), and 43% of pts stayed SFT-free during FU. Local recurrence occurred in 26.7% after a mFU of 35.5 m (1.0–153.8), associated with an OS of 45.1 m (4.7–118.2). Metachronous metastasis occurred in 30.2% after a mFU of 36.0 m (0.1–157.1). OS in metastatic pts was 19.0 m (0.3–149.0). Systemic therapy was given to 26 pts (27.7%) with inoperable/metastatic disease. The most common (57.7%) upfront therapy was doxorubicin, achieving responses in 13.3% of pts with a PFS of 4.8 m (0.4–23.8). In second line, pts were treated with ifosfamide or pazopanib, the latter achieving the highest response rates. Third-line treatment was heterogeneous. Conclusion. SFT is an orphan malignancy with a highly variable clinical course and a considerable risk of local failure and metachronous metastasis. Surgery is the only curative option; palliative systemic therapy is used in inoperable/metastatic cases but achieves low response rates. The highest response rates are seen with pazopanib in second/third line.
- Published
- 2020
- Full Text
- View/download PDF
17. PD-0889 Functional lung dose and postoperative lung complications in esophageal cancer trimodality therapy
- Author
-
Populaire, P., primary, Defraene, G., additional, Nafteux, P., additional, Depypere, L., additional, and Haustermans, K., additional
- Published
- 2023
- Full Text
- View/download PDF
18. Current practice in antireflux and hiatal hernia surgery: exploration of the Belgian field.
- Author
-
Depypere, L., Van Veer, H., Nafteux, P., and Coosemans, W.
- Published
- 2023
- Full Text
- View/download PDF
19. Esophageal Squamous Cell Carcinoma After Adjustable Gastric Banding
- Author
-
Janse, Paulien, Nafteux, Philippe, Lannoo, Matthias, Steger, Piet-Hein, and Sirbu, Fernando
- Published
- 2019
- Full Text
- View/download PDF
20. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
- Author
-
Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, Rossum, P.S.N. van, Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, and Rossum, P.S.N. van
- Abstract
Item does not contain fulltext, BACKGROUND: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. METHODS: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). RESULTS: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). CONCLUSION: The OMEC project has resul
- Published
- 2023
21. Oncologic and Functional Outcomes After Primary and Salvage Laryngopharyngoesophagectomy With Gastric Pull-Up Reconstruction for Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Author
-
Jeroen Meulemans, Floor Couvreur, Eline Beckers, Philippe Nafteux, Hans Van Veer, Vincent Vander Poorten, Pierre Delaere, and Willy Coosemans
- Subjects
hypopharynx ,squamous cell carcinoma ,laryngopharyngoesophagectomy ,gastric pull-up ,salvage surgery ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background/Purpose: Hypopharyngeal squamous cell carcinomas (SCC) are generally diagnosed in an advanced disease stage. A total laryngopharyngoesophagectomy with gastric pull-up reconstruction is a time tested surgical treatment in our centre for resectable failures or recurrences after primary treatment with organ preservation protocols (radiotherapy or chemoradiation), or as a primary surgical treatment for very advanced hypopharyngeal tumors. We present the results of our approach in terms of success rate, postoperative complications and functional and oncologic outcomes.Methods: We retrospectively reviewed the charts of all patients with hypopharyngeal SCC, who underwent laryngopharyngoesophagectomy with gastric pull-up reconstruction during the period 1989–2015.Results: The cohort included 60 patients. Mean follow-up was 32 months. Stage III and stage IV disease was present in 35 and 60% of patients, respectively. Successful reconstruction by intended gastric transposition was possible in 98.3% of cases. The in-hospital mortality rate was 8.3%. Two-year and five-year actuarial overall survival were 39.5 and 21.1%, respectively. Two-year and five-year actuarial disease specific survival were 58.5 and 46.6%, respectively. Two-year and five-year actuarial locoregional recurrence free survival were both 49.5%. A significantly lower locoregional recurrence free survival was observed in patients with pN+ disease compared to pN0 (Log rank, p
- Published
- 2019
- Full Text
- View/download PDF
22. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study
- Author
-
Hagens, Eliza R. C., van Berge Henegouwen, Mark I., van Sandick, Johanna W., Cuesta, Miguel A., van der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Scheepers, Joris J. G., Sosef, Meindert N., van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, de Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin-ichi, Chen, Haiquan, Law, Simon Y. K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J. G. H. M., Hulshof, Maarten C. C. M., van Laarhoven, Hanneke W. M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G. W., and Gisbertz, Suzanne S.
- Published
- 2019
- Full Text
- View/download PDF
23. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
- Author
-
Depypere, Lieven, Thomas, Melissa, Moons, Johnny, Coosemans, Willy, Lerut, Toni, Prenen, Hans, Haustermans, Karin, Van Veer, Hans, and Nafteux, Philippe
- Published
- 2019
- Full Text
- View/download PDF
24. Lung Transplant Outcome From Selected Older Donors (≥70 Years) Equals Younger Donors (<70 Years): A Propensity-matched Analysis.
- Author
-
Vanluyten, Cedric, Vandervelde, Christelle M., Vos, Robin, Van Slambrouck, Jan, Fieuws, Steffen, De Leyn, Paul, Nafteux, Philippe, Decaluwé, Herbert, Van Veer, Hans, Depypere, Lieven, Jansen, Yanina, Provoost, An-Lies, Neyrinck, Arne P., Ingels, Catherine, Vanaudenaerde, Bart M., Godinas, Laurent, Dupont, Lieven J., Verleden, Geert M., Van Raemdonck, Dirk, and Ceulemans, Laurens J.
- Abstract
Objective: To describe our experience with lung transplantation (LTx) from donors ≥70 years and compare short and long-term outcomes to a propensity-matched cohort of donors <70 years. Background: Although extended-criteria donors have been widely used to enlarge the donor pool, the experience with LTx from older donors (≥70 years) remains limited. Methods: All single-center bilateral LTx between 2010 and 2020 were retrospectively analyzed. Matching (1:1) was performed for the donor (type, sex, smoking history, x-ray abnormalities, partial pressure of oxygen/fraction of inspired oxygen ratio, and time on ventilator) and recipient characteristics (age, sex, LTx indication, perioperative extracorporeal life support, and cytomegalovirus mismatch). Primary graft dysfunction grade-3, 5-year patient, and chronic lung allograft dysfunction-free survival were analyzed. Results: Out of 647 bilateral LTx, 69 were performed from donors ≥70 years. The mean age in the older donor cohort was 74 years (range: 70–84 years) versus 49 years (range: 12–69 years) in the matched younger group. No significant differences were observed in the length of ventilatory support, intensive care unit, or hospital stay. Primary graft dysfunction-3 was 26% in the older group versus 29% in younger donor recipients (P = 0.85). Reintervention rate was comparable (29% vs 16%; P = 0.10). Follow-up bronchoscopy revealed no difference in bronchial anastomotic complications (P = 1.00). Five-year patient and chronic lung allograft dysfunction-free survivals were 73.6% versus 73.1% (P = 0.72) and 51.5% versus 59.2% (P = 0.41), respectively. Conclusions: LTx from selected donors ≥70 years is feasible and safe, yielding comparable short and long-term outcomes in a propensity-matched analysis with younger donors (<70 years). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Primary Surgery Not Inferior to Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
- Author
-
Bouckaert, Andreas, Moons, Johnny, Lerut, Toni, Coosemans, Willy, Depypere, Lieven, Van Veer, Hans, and Nafteux, Philippe
- Abstract
The current gold standard for treatment of locally advanced esophageal adenocarcinoma is neoadjuvant chemotherapy or chemoradiotherapy followed by surgery. The shift toward neoadjuvant chemoradiotherapy (nCRT) was driven by the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial. This study reassessed, in daily practice, the presumed advantage of nCRT followed by surgery on long-term survival compared with primary surgery, in a group of all adenocarcinomas treated through a transthoracic approach with extensive 2-field lymphadenectomy. This retrospective cohort study with propensity score-matched analysis included all surgically treated patients between 2000 and 2018 with locally advanced adenocarcinoma (cT1/2 N+ or cT3/4 N0/+). For appropriate comparison, exclusion criteria of the CROSS trial were applied. Patients were matched on age, Charlson comorbidity score, clinical tumor length, and lymph node status. The primary end point was 5-year overall survival. There were 473 eligible patients who underwent primary surgery (225 patients) or nCRT + surgery (248 patients). After propensity score-matched analysis, 149 matched cases were defined in each group for analysis. There was no significant difference after 5 years between the matched groups in median overall survival (32.5 and 35.0 months, P =.41) and median disease-free survival (14.3 and 13.5 months, P =.16). nCRT was associated with significantly more postoperative complications (mean Comprehensive Complication Index score: 21.0 vs 30.5, P <.0001) and longer mean stay in the hospital (14.0 vs 18.2 days, P =.05) and intensive care unit (11.7 vs 37.7 days, P =.05). Our propensity score-matched results indicate that primary surgery, performed through transthoracic approach with extensive 2-field lymphadenectomy, can offer a comparable overall and disease-free survival after 5 years, with potentially fewer postoperative complications and shorter hospital and intensive care unit stay compared with nCRT followed by surgery. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?: A planning study
- Author
-
Botticella, A., Defraene, G., Nackaerts, K., Deroose, C., Coolen, J., Nafteux, P., Vanstraelen, B., Joosten, S., Michiels, L. A. W., Peeters, S., and De Ruysscher, D.
- Published
- 2017
- Full Text
- View/download PDF
27. Current practice in antireflux and hiatal hernia surgery: exploration of the Belgian field
- Author
-
Depypere, L., primary, Van Veer, H., additional, Nafteux, P., additional, and Coosemans, W., additional
- Published
- 2022
- Full Text
- View/download PDF
28. An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE).
- Author
-
Elliott, Jessie A., Markar, Sheraz R., Klevebro, Fredrik, Johar, Asif, Goense, Lucas, Lagergren, Pernilla, Zaninotto, Giovanni, van Hillegersberg, Richard, van Berge Henegouwen, Mark I., Nilsson, Magnus, Hanna, George B., Reynolds, John V., Van Veer, Hans, Depypere, Lieven, Coosemans, Willy, Nafteux, Philippe, Carroll, Paul, Allison, Frances, Darling, Gail, and Findlay, John M
- Abstract
Objective: To determine the impact of surveillance on recurrence pattern, treatment, survival and health-related quality-of-life (HRQL) following curative-intent resection for esophageal cancer. Summary Background Data: Although therapies for recurrent esophageal cancer may impact survival and HRQL, surveillance protocols after primary curative treatment are varied and inconsistent, reflecting a lack of evidence. Methods: European iNvestigation of SUrveillance after Resection for Esophageal cancer was an international multicenter study of consecutive patients undergoing surgery for esophageal and esophagogastric junction cancers (2009–2015) across 20 centers (NCT03461341). Intensive surveillance (IS) was defined as annual computed tomography for 3 years postoperatively. The primary outcome measure was overall survival (OS), secondary outcomes included treatment, disease-specific survival, recurrence pattern, and HRQL. Multivariable linear, logistic, and Cox proportional hazards regression analyses were performed. Results: Four thousand six hundred eighty-two patients were studied (72.6% adenocarcinoma, 69.1% neoadjuvant therapy, 45.5% IS). At median followup 60 months, 47.5% developed recurrence, oligometastatic in 39%. IS was associated with reduced symptomatic recurrence (OR 0.17 [0.12–0.25]) and increased tumor-directed therapy (OR 2.09 [1.58–2.77]). After adjusting for confounders, no OS benefit was observed among all patients (HR 1.01 [0.89–1.13]), but OS was improved following IS for those who underwent surgery alone (HR 0.60 [0.47–0.78]) and those with lower pathological (y)pT stages (Tis-2, HR 0.72 [0.58–0.89]). IS was associated with greater anxiety (P =0.016), but similar overall HRQL. Conclusions: IS was associated with improved oncologic outcome in select cohorts, specifically patients with early-stage disease at presentation or favorable pathological stage post neoadjuvant therapy. This may inform guideline development, and enhance shared decision-making, at a time when therapeutic options for recurrence are expanding. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Defining Major Surgery: A Delphi Consensus Among European Surgical Association (ESA) Members
- Author
-
Martin, D., Mantziari, S., Demartines, N., Hubner, M., Bismuth, H., Sarr, M. G., Strasberg, S. M., Wexner, S. D., Adham, M., Altomare, D. F., Andersson, R., Bechstein, W., Biondo, S., Bockhorn, M., Bonavina, L., Rituerto, D. C., Clavien, P. -A., De Manzini, N., Decker, G., Dejong, C. H., Dervenis, C., Farges, O., Figueras, J., Fingerhut, A. L., Friess, H., Glehen, O., Gnant, M., Gutschow, C., Hahnloser, D., Hamberger, B., Hamming, J. F., Holscher, A. H., Izbicki, J. R., Jonas, S., Karamarkovic, A., Kehlet, H., Leppaniemi, A. K., Lerut, J., Line, P. -D., Lodge, J. P. A., Meakins, J. L., Montorsi, M., Nafteux, P., Naredi, P., Olah, A., Panis, Y., Pardo, F., Parks, R. W., Pedrazzoli, S., Pessaux, P., Marques, H. P., Poggioli, G., Popescu, I., Puolakkainen, P. A., Ramia Angel, J. M., Rasanen, J., Reynolds, J. V., Rosati, R., Saeger, H. -D., Schneeberger, S., Schneider, P. M., Soreide, K., Stippel, D., Toso, C., Tuech, J. -J., Tukiainen, E. J., Van Hillegersberg, R., Wijnhoven, B., Winter, D. C., Zaninotto, G., Surgery, Martin, D., Mantziari, S., Demartines, N., Hubner, M., Bismuth, H., Sarr, M. G., Strasberg, S. M., Wexner, S. D., Adham, M., Altomare, D. F., Andersson, R., Bechstein, W., Biondo, S., Bockhorn, M., Bonavina, L., Rituerto, D. C., Clavien, P. -A., De Manzini, N., Decker, G., Dejong, C. H., Dervenis, C., Farges, O., Figueras, J., Fingerhut, A. L., Friess, H., Glehen, O., Gnant, M., Gutschow, C., Hahnloser, D., Hamberger, B., Hamming, J. F., Holscher, A. H., Izbicki, J. R., Jonas, S., Karamarkovic, A., Kehlet, H., Leppaniemi, A. K., Lerut, J., Line, P. -D., Lodge, J. P. A., Meakins, J. L., Montorsi, M., Nafteux, P., Naredi, P., Olah, A., Panis, Y., Pardo, F., Parks, R. W., Pedrazzoli, S., Pessaux, P., Marques, H. P., Poggioli, G., Popescu, I., Puolakkainen, P. A., Ramia Angel, J. M., Rasanen, J., Reynolds, J. V., Rosati, R., Saeger, H. -D., Schneeberger, S., Schneider, P. M., Soreide, K., Stippel, D., Toso, C., Tuech, J. -J., Tukiainen, E. J., Van Hillegersberg, R., Wijnhoven, B., Winter, D. C., Zaninotto, G., Martin D., Mantziari S., Demartines N., Hubner M., Bismuth H., Sarr M.G., Strasberg S.M., Wexner S.D., Adham M., Altomare D.F., Andersson R., Bechstein W., Biondo S., Bockhorn M., Bonavina L., Rituerto D.C., Clavien P.-A., De Manzini N., Decker G., Dejong C.H., Dervenis C., Farges O., Figueras J., Fingerhut A.L., Friess H., Glehen O., Gnant M., Gutschow C., Hahnloser D., Hamberger B., Hamming J.F., Holscher A.H., Izbicki J.R., Jonas S., Karamarkovic A., Kehlet H., Leppaniemi A.K., Lerut J., Line P.-D., Lodge J.P.A., Meakins J.L., Montorsi M., Nafteux P., Naredi P., Olah A., Panis Y., Pardo F., Parks R.W., Pedrazzoli S., Pessaux P., Marques H.P., Poggioli G., Popescu I., Puolakkainen P.A., Ramia Angel J.M., Rasanen J., Reynolds J.V., Rosati R., Saeger H.-D., Schneeberger S., Schneider P.M., Soreide K., Stippel D., Toso C., Tuech J.-J., Tukiainen E.J., Van Hillegersberg R., Wijnhoven B., Winter D.C., Zaninotto G., ESA Study Group, Sarr, M.G., Strasberg, S.M., Wexner, S.D., Altomare, D.F., Rituerto, D.C., Clavien, P.A., Dejong, C.H., Fingerhut, A.L., Hamming, J.F., Hölscher, A.H., Izbicki, J.R., Leppäniemi, A.K., Line, P.D., Lodge, JPA, Meakins, J.L., Oláh, A., Parks, R.W., Marques, H.P., Puolakkainen, P.A., Ramia Angel, J.M., Reynolds, J.V., Saeger, H.D., Schneider, P.M., Søreide, K., Tuech, J.J., Tukiainen, E.J., Winter, D.C., Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Zurich, Demartines, Nicolas, and Toso, Christian
- Subjects
Male ,medicine.medical_specialty ,Blood transfusion ,Consensus ,Delphi Technique ,medicine.medical_treatment ,Delphi method ,610 Medicine & health ,Consensu ,Likert scale ,03 medical and health sciences ,Surgeon ,0302 clinical medicine ,Aged ,Europe ,Humans ,Middle Aged ,Societies, Medical ,Surgeons ,Surgical Procedures, Operative/methods ,Medical ,major surgery ,Delphi consensus definition ,medicine ,Operative / methods ,10217 Clinic for Visceral and Transplantation Surgery ,Surgical Procedures ,ddc:617 ,business.industry ,Perioperative ,Vascular surgery ,2746 Surgery ,3. Good health ,Cardiac surgery ,Surgery ,Cardiothoracic surgery ,030220 oncology & carcinogenesis ,Surgical Procedures, Operative ,030211 gastroenterology & hepatology ,Societies ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Abdominal surgery ,Human - Abstract
Background: Major surgery is a term frequently used but poorly defined. The aim of the present study was to reach a consensus in the definition of major surgery within a panel of expert surgeons from the European Surgical Association (ESA). Methods: A 3-round Delphi process was performed. All ESA members were invited to participate in the expert panel. In round 1, experts were inquired by open- and closed-ended questions on potential criteria to define major surgery. Results were analyzed and presented back anonymously to the panel within next rounds. Closed-ended questions in round 2 and 3 were either binary or statements to be rated on a Likert scale ranging from 1 (strong disagreement) to 5 (strong agreement). Participants were sent 3 reminders at 2-week intervals for each round. 70% of agreement was considered to indicate consensus. Results: Out of 305 ESA members, 67 (22%) answered all the 3 rounds. Significant comorbidities were the only preoperative factor retained to define major surgery (78%). Vascular clampage or organ ischemia (92%), high intraoperative blood loss (90%), high noradrenalin requirements (77%), long operative time (73%) and perioperative blood transfusion (70%) were procedure-related factors that reached consensus. Regarding postoperative factors, systemic inflammatory response (76%) and the need for intensive or intermediate care (88%) reached consensus. Consequences of major surgery were high morbidity (>30% overall) and mortality (>2%). Conclusion: ESA experts defined major surgery according to extent and complexity of the procedure, its pathophysiological consequences and consecutive clinical outcomes.
- Published
- 2020
30. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
- Author
-
Kroese, T.E., Hillegersberg, R. van, Schoppmann, S., Deseyne, P., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkins, M.A., Smyth, E., Markar, S., Hanna, G.B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C.J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Jeene, P., Sandick, J.W. van, Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L.V., Kolodziejczyk, P., Polkowski, W.P., Alsina, M., Pera, M., Kanonnikoff, T.F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E.A., Rütten, H., Rosman, C., Verheij, M., Rossum, P.S.N. van, Laarhoven, H.W. van, Kroese, T.E., Hillegersberg, R. van, Schoppmann, S., Deseyne, P., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkins, M.A., Smyth, E., Markar, S., Hanna, G.B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C.J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Jeene, P., Sandick, J.W. van, Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L.V., Kolodziejczyk, P., Polkowski, W.P., Alsina, M., Pera, M., Kanonnikoff, T.F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E.A., Rütten, H., Rosman, C., Verheij, M., Rossum, P.S.N. van, and Laarhoven, H.W. van
- Abstract
Item does not contain fulltext, BACKGROUND: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. OBJECTIVE: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. MATERIAL AND METHODS: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%-75%), or consensus (≥75%). RESULTS: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. CONCLUSION: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oeso
- Published
- 2022
31. Identifying a core symptom set triggering radiological and endoscopic investigations for suspected recurrent esophago-gastric cancer:a modified Delphi consensus process
- Author
-
Chidambaram, S. (Swathikan), Patel, N. M. (Nikhil M.), Sounderajah, V. (Viknesh), Alfieri, R. (Rita), Bonavina, L. (Luigi), Cheong, E. (Edward), Cockbain, A. (Andy), D’Journo, X. B. (Xavier Benoit), Ferri, L. (Lorenzo), Griffiths, E. A. (Ewen A.), Grimminger, P. (Peter), Gronnier, C. (Caroline), Gutschow, C. (Christian), Hedberg, J. (Jakob), Kauppila, J. H. (Joonas H.), Lagarde, S. (Sjoerd), Low, D. (Donald), Nafteux, P. (Philippe), Nieuwenhuijzen, G. (Grard), Nilsson, M. (Magnus), Rosati, R. (Riccardo), Schroeder, W. (Wolfgang), Smithers, B. M. (B. Mark), van Berge Henegouwen, M. I. (Mark I.), van Hillegesberg, R. (Richard), Watson, D. I. (David I.), Vohra, R. (Ravinder), Maynard, N. (Nick), Markar, S. R. (Sheraz R.), Chidambaram, S. (Swathikan), Patel, N. M. (Nikhil M.), Sounderajah, V. (Viknesh), Alfieri, R. (Rita), Bonavina, L. (Luigi), Cheong, E. (Edward), Cockbain, A. (Andy), D’Journo, X. B. (Xavier Benoit), Ferri, L. (Lorenzo), Griffiths, E. A. (Ewen A.), Grimminger, P. (Peter), Gronnier, C. (Caroline), Gutschow, C. (Christian), Hedberg, J. (Jakob), Kauppila, J. H. (Joonas H.), Lagarde, S. (Sjoerd), Low, D. (Donald), Nafteux, P. (Philippe), Nieuwenhuijzen, G. (Grard), Nilsson, M. (Magnus), Rosati, R. (Riccardo), Schroeder, W. (Wolfgang), Smithers, B. M. (B. Mark), van Berge Henegouwen, M. I. (Mark I.), van Hillegesberg, R. (Richard), Watson, D. I. (David I.), Vohra, R. (Ravinder), Maynard, N. (Nick), and Markar, S. R. (Sheraz R.)
- Abstract
Summary Background: There is currently a lack of evidence-based guidelines regarding surveillance for recurrence after esophageal and gastric (OG) cancer surgical resection, and which symptoms should prompt endoscopic or radiological investigations for recurrence. The aim of this study was to develop a core symptom set using a modified Delphi consensus process that should guide clinicians to carry out investigations to look for suspected recurrent OG cancer in previously asymptomatic patients. Methods: A web-based survey of 42 questions was sent to surgeons performing OG cancer resections at high volume centers. The first section evaluated the structure of follow-up and the second, determinants of follow-up. Two rounds of a modified Delphi consensus process and a further consensus workshop were used to determine symptoms warranting further investigations. Symptoms with a 75% consensus agreement as suggestive of recurrent cancer were included in the core symptom set. Results: 27 surgeons completed the questionnaires. A total of 70.3% of centers reported standardized surveillance protocols, whereas 3.7% of surgeons did not undertake any surveillance in asymptomatic patients after OG cancer resection. In asymptomatic patients, 40.1% and 25.9% of centers performed routine imaging and endoscopy, respectively. The core set that reached consensus, consisted of eight symptoms that warranted further investigations included; dysphagia to solid food, dysphagia to liquids, vomiting, abdominal pain, chest pain, regurgitation of foods, unexpected weight loss and progressive hoarseness of voice. Conclusion: There is global variation in monitoring patients after OG cancer resection. Eight symptoms were identified by the consensus process as important in prompting radiological or endoscopic investigation for suspected recurrent malignancy. Further randomized controlled trials are necessary to link surveillance strategies to survival outcomes and evaluate prognostic value.
- Published
- 2022
32. Evaluation of parenteral nutrition use in patients undergoing major upper gastro-intestinal surgery
- Author
-
Deleenheer, Barbara, Declercq, Peter, Van Veer, Hans, Nafteux, Philippe, and Spriet, Isabel
- Published
- 2015
- Full Text
- View/download PDF
33. Diagnostic and Therapeutic Challenges in Treating an Esophago-Pleural Fistula Following Lung Transplantation
- Author
-
Vanluyten, C., primary, Vanstraelen, S., additional, Nafteux, P., additional, Van Slambrouck, J., additional, De Leyn, P., additional, Coosemans, W., additional, Decaluwé, H., additional, Van Veer, H., additional, Depypere, L., additional, Debaveye, Y., additional, De Vlieger, G., additional, Casaer, M., additional, Neyrinck, A., additional, Godinas, L., additional, Vos, R., additional, Verleden, G., additional, Bisschops, R., additional, Van Raemdonck, D., additional, and Ceulemans, L., additional
- Published
- 2022
- Full Text
- View/download PDF
34. Recipient Outcome After Lung Transplantation from Older Donors (≥70 Years) Equals Younger Donors (< 70 Years): A Propensity-Matched Analysis
- Author
-
Vanluyten, C., primary, Vandervelde, C., additional, Vos, R., additional, Fieuws, S., additional, Van Slambrouck, J., additional, De Leyn, P., additional, Coosemans, W., additional, Nafteux, P., additional, Decaluwé, H., additional, Van Veer, H., additional, Depypere, L., additional, Denaux, K., additional, Desschans, B., additional, Ingels, C., additional, Verleden, S., additional, Godinas, L., additional, Dupont, L., additional, Verleden, G., additional, Neyrinck, A., additional, Van Raemdonck, D., additional, and Ceulemans, L., additional
- Published
- 2022
- Full Text
- View/download PDF
35. A Challenging Case of PTLD-Related Broncho-Esophageal Fistula After Lung Transplantation
- Author
-
Van Slambrouck, J., primary, Peetermans, M., additional, Dierickx, D., additional, Depypere, L., additional, Happaerts, S., additional, Ralki, M., additional, Orlitová, M., additional, Godinas, L., additional, Vos, R., additional, Verleden, G.M., additional, Van Raemdonck, D., additional, Nafteux, P., additional, and Ceulemans, L.J., additional
- Published
- 2022
- Full Text
- View/download PDF
36. Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastro- esophageal cancer in a large Belgian cohort
- Author
-
De Meulder, S, primary, Sagaert, X, additional, Brems, H, additional, Brekelmans, C, additional, Nafteux, P, additional, Topal, B, additional, Verslype, C, additional, Tejpar, S, additional, Van Cutsem, E, additional, and Dekervel, J, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
- Author
-
Kroese, T.E. van Hillegersberg, R. Schoppmann, S. Deseyne, P.R.A.J. Nafteux, P. Obermannova, R. Nordsmark, M. Pfeiffer, P. Hawkings, M.A. Smyth, E. Markar, S. Hanna, G.B. Cheong, E. Chaudry, A. Elme, A. Adenis, A. Piessen, G. Gani, C. Bruns, C.J. Moehler, M. Liakakos, T. Reynolds, J. Morganti, A. Rosati, R. Castoro, C. D'Ugo, D. Roviello, F. Bencivenga, M. de Manzoni, G. Jeene, P. van Sandick, J.W. Muijs, C. Slingerland, M. Nieuwenhuijzen, G. Wijnhoven, B. Beerepoot, L.V. Kolodziejczyk, P. Polkowski, W.P. Alsina, M. Pera, M. Kanonnikoff, T.F. Nilsson, M. Guckenberger, M. Monig, S. Wagner, D. Wyrwicz, L. Berbee, M. Gockel, I. Lordick, F. Griffiths, E.A. Verheij, M. van Rossum, P.S.N. van Laarhoven, H.W.M. Rosman, C. Rütten, H. Gootjes, E.C. Vonken, F.E.M. van Dieren, J.M. Vollebergh, M.A. van der Sangen, M. Creemers, G.-J. Zander, T. Schlößer, H. Cascinu, S. Mazza, E. Nicoletti, R. Damascelli, A. Slim, N. Passoni, P. Cossu, A. Puccetti, F. Barbieri, L. Fanti, L. Azzolini, F. Ventoruzzo, F. Szczepanik, A. Visa, L. Reig, A. Roques, T. Harrison, M. Ciseł, B. Pikuła, A. Skórzewska, M. Vanommeslaeghe, H. Van Daele, E. Pattyn, P. Geboes, K. Callebout, E. Ribeiro, S. van Duijvendijk, P. Tromp, C. Sosef, M. Warmerdam, F. Heisterkamp, J. Vera, A. Jordá, E. López-Mozos, F. Fernandez-Moreno, M.C. Barrios-Carvajal, M. Huerta, M. de Steur, W. Lips, I. Diez, M. Castro, S. O'Neill, R. Holyoake, D. Hacker, U. Denecke, T. Kuhnt, T. Hoffmeister, A. Kluge, R. Bostel, T. Grimminger, P. Jedlička, V. Křístek, J. Pospíšil, P. Mourregot, A. Maurin, C. Starling, N. Chong, I. OMEC working group
- Abstract
Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (
- Published
- 2022
38. Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer.
- Author
-
Kroese, Tiuri E., van Rossum, Peter S.N., Nilsson, Magnus, Lordick, Florian, Smyth, Elizabeth C., Rosati, Riccardo, Nafteux, Philippe, D'Ugo, Domenico, Chaudry, M. Asif, Polkowkski, Wojciech, Roviello, Franco, Gockel, Ines, Kolodziejczyk, Piotr, Haustermans, Karin, Guckenberger, Matthias, Nordsmark, Marianne, Hawkins, Maria A., Cervantes, Andres, Fleitas, Tania, and van Cutsem, Eric
- Subjects
RESEARCH protocols ,DELPHI method ,STEREOTACTIC radiotherapy ,DEFINITIONS ,TREATMENT effectiveness - Abstract
A uniform definition and treatment for oligometastatic esophagogastric cancer is currently lacking. However, a comprehensive definition of oligometastatic esophagogastric cancer is necessary to initiate studies on local treatment strategies (e.g. metastasectomy or stereotactic radiotherapy) and new systemic therapy agents in this group of patients. For this purpose, the OligoMetastatic Esophagogastric Cancer (OMEC) project was established. The OMEC-project aims to develop a multidisciplinary European consensus statement on the definition, diagnosis, and treatment for oligometastatic esophagogastric cancer and provide a framework for prospective studies to improve outcomes of these patients. The OMEC-project consists of five studies, including 1) a systematic review on definitions and outcomes of oligometastatic esophagogastric cancer; 2) real-life clinical scenario discussions in multidisciplinary expert teams to determine the variation in the definition and treatment strategies; 3) Delphi consensus process through a starting meeting, two Delphi questionnaire rounds, and a consensus meeting; 4) publication of a multidisciplinary European consensus statement; and 5) a prospective clinical trial in patients with oligometastatic esophagogastric cancer. The OMEC project aims to establish a multidisciplinary European consensus statement for oligometastatic esophagogastric cancer and aims to initiate a prospective clinical trial to improve outcomes for these patients. Recommendations from OMEC can be used to update the relevant guidelines on treatment for patients with (oligometastatic) esophagogastric cancer. • OligoMetastatic Esophagogastric Cancer (OMEC) project was established • The OMEC project consists of five studies • Recommendations from OMEC can be used to update the relevant guidelines • OMEC aims to initiate a prospective trial to improve outcomes for these patients [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Exploring the concept of centralization of surgery for benign esophageal diseases: a Delphi based consensus from the European Society for Diseases of the Esophagus (Feb, doab013, 2021)
- Author
-
Lugaresi, M, Nafteux, P, Nilsson, M, Reynolds, JV, Rosati, R, Schoppmann, SF, Targarona, EM, and Mattioli, S
- Published
- 2021
40. Technique of open and minimally invasive intrathoracic reconstruction following esophagectomy-an expert consensus based on a modified Delphi process
- Author
-
Bartella, I., Fransen, L.F.C., Gutschow, C.A., Bruns, C.J., Berge Henegouwen, M.I. van, Chaudry, M.A., Cheong, E., Cuesta, M.A., Daele, E. van, Gisbertz, S.S., Hillegersberg, R. van, Hölscher, A., Mercer, S., Moorthy, K., Nafteux, P., Nilsson, M., Pattyn, P., Piessen, G., Räsanen, J., Rosman, C., Ruurda, J.P., Schneider, P.M., Sgromo, B., Nieuwenhuijzen, G.A., Luyer, M.D., Schröder, W., Bartella, I., Fransen, L.F.C., Gutschow, C.A., Bruns, C.J., Berge Henegouwen, M.I. van, Chaudry, M.A., Cheong, E., Cuesta, M.A., Daele, E. van, Gisbertz, S.S., Hillegersberg, R. van, Hölscher, A., Mercer, S., Moorthy, K., Nafteux, P., Nilsson, M., Pattyn, P., Piessen, G., Räsanen, J., Rosman, C., Ruurda, J.P., Schneider, P.M., Sgromo, B., Nieuwenhuijzen, G.A., Luyer, M.D., and Schröder, W.
- Abstract
Item does not contain fulltext, BACKGROUND: In recent years, minimally invasive Ivor Lewis (IL) esophagectomy with high intrathoracic anastomosis has emerged as surgical standard of care for esophageal cancer in expert centers. Alongside this process, many divergent technical aspects of this procedure have been devised in different centers. This study aims at achieving international consensus on the surgical steps of IL reconstruction using Delphi methodology. METHODS: The expert panel consisted of specialized esophageal surgeons from 8 European countries. During a two-round Delphi process, a detailed analysis and consensus on key steps of intrathoracic gastric tube reconstruction (IL esophagectomy) was performed. RESULTS: Response rates in Delphi rounds 1 and 2 were 100% (22 of 22 experts) and 83.3% (20 of 24 experts), respectively. Three essential technical areas of intrathoracic gastric tube reconstruction were identified: first, vascularization of the gastric conduit, second, gastric mobilization, tube formation and pull-up, and third, anastomotic technique. In addition, 3 main techniques for minimally invasive intrathoracic anastomosis are currently practiced: (i) end-to-side circular stapled, (ii) end-to-side double stapling, and (iii) side-to-side linear stapled technique. The step-by-step procedural analysis unveiled common approaches but also different expert practice. CONCLUSION: This precise technical description may serve as a clinical guideline for intrathoracic reconstruction after esophagectomy. In addition, the results may aid to harmonize the technical evolution of this complex surgical procedure and thereby facilitate surgical training.
- Published
- 2021
41. The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study
- Author
-
Fransen, L.F.C., Berkelmans, G.H., Asti, E., Henegouwen, M., Berlth, F., Bonavina, L., Brown, A., Bruns, C., Daele, E. van, Gisbertz, S.S., Grimminger, P.P., Gutschow, C.A., Hannink, G.J., Hölscher, A.H., Kauppi, J., Lagarde, S.M., Mercer, S., Moons, J., Nafteux, P., Nilsson, M., Palazzo, F., Pattyn, P., Raptis, D.A., Räsanen, J., Rosato, E.L., Rouvelas, I., Schmidt, H.M., Schneider, P.M., Schröder, W., Sluis, P.C. van der, Wijnhoven, B.P., Nieuwenhuijzen, G.A., Luyer, M.D., Fransen, L.F.C., Berkelmans, G.H., Asti, E., Henegouwen, M., Berlth, F., Bonavina, L., Brown, A., Bruns, C., Daele, E. van, Gisbertz, S.S., Grimminger, P.P., Gutschow, C.A., Hannink, G.J., Hölscher, A.H., Kauppi, J., Lagarde, S.M., Mercer, S., Moons, J., Nafteux, P., Nilsson, M., Palazzo, F., Pattyn, P., Raptis, D.A., Räsanen, J., Rosato, E.L., Rouvelas, I., Schmidt, H.M., Schneider, P.M., Schröder, W., Sluis, P.C. van der, Wijnhoven, B.P., Nieuwenhuijzen, G.A., and Luyer, M.D.
- Abstract
Item does not contain fulltext, BACKGROUND: Esophagectomy is a technically challenging procedure, associated with significant morbidity. The introduction of minimally invasive esophagectomy (MIE) has reduced postoperative morbidity. OBJECTIVE: Although the short-term effect on complications is increasingly being recognized, the impact on long-term survival remains unclear. This study aims to investigate the association between postoperative complications following MIE and long-term survival. METHODS: Data were collected from the EsoBenchmark Collaborative composed by 13 high-volume, expert centers routinely performing MIE. Patients operated between June 1, 2011 and May 31, 2016 were included. Complications were graded using the Clavien-Dindo (CD) classification. To correct for short-term effects of postoperative complications on mortality, patients who died within 90 days postoperative were excluded. Primary endpoint was 5-year overall survival. RESULTS: A total of 915 patients were included with a mean follow-up time of 30.8 months (standard deviation 17.9). Complications occurred in 542 patients (59.2%) of which 50.2% had a CD grade ≥III complication [ie, (re)intervention, organ dysfunction, or death]. The incidence of anastomotic leakage (AL) was 135 of 915 patients (14.8%) of which 84 patients were classified as a CD grade ≥III. Multivariable analysis showed a significantly deteriorated long-term survival in all patients with AL [hazard ratio (HR) 1.68, 95% confidence interval (CI) 1.25-2.24]. This inverse relation was most distinct when AL was scored as a CD grade ≥III (HR 1.83, 95% CI 1.30-2.58). For all other complications, no significant association with long-term survival was found. CONCLUSION: The occurrence and severity of AL, but not overall complications, after MIE negatively affect long-term survival of esophageal cancer patients.
- Published
- 2021
42. Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus
- Author
-
Mueller, P. C., Kapp, J. R., Vetter, D., Bonavina, L., Brown, W., Castro, S., Cheong, E., Darling, G. E., Egberts, J., Ferri, L., Gisbertz, S. S., Gockel, I, Grimminger, P. P., Hofstetter, W. L., Hoelscher, A. H., Low, D. E., Luyer, M., Markar, S. R., Moenig, S. P., Moorthy, K., Morse, C. R., Mueller-Stich, B. P., Nafteux, P., Nieponice, A., Nieuwenhuijzen, G. A. P., Nilsson, M., Palanivelu, C., Pattyn, P., Pera, M., Rasanen, J., Ribeiro, U., Rosman, C., Schroeder, W., Sgromo, B., van Berge Henegouwen, M., I, van Hillegersberg, R., van Veer, H., van Workum, F., Watson, D., I, Wijnhoven, B. P. L., Gutschow, C. A., Mueller, P. C., Kapp, J. R., Vetter, D., Bonavina, L., Brown, W., Castro, S., Cheong, E., Darling, G. E., Egberts, J., Ferri, L., Gisbertz, S. S., Gockel, I, Grimminger, P. P., Hofstetter, W. L., Hoelscher, A. H., Low, D. E., Luyer, M., Markar, S. R., Moenig, S. P., Moorthy, K., Morse, C. R., Mueller-Stich, B. P., Nafteux, P., Nieponice, A., Nieuwenhuijzen, G. A. P., Nilsson, M., Palanivelu, C., Pattyn, P., Pera, M., Rasanen, J., Ribeiro, U., Rosman, C., Schroeder, W., Sgromo, B., van Berge Henegouwen, M., I, van Hillegersberg, R., van Veer, H., van Workum, F., Watson, D., I, Wijnhoven, B. P. L., and Gutschow, C. A.
- Abstract
There are no internationally recognized criteria available to determine preparedness for hospital discharge after esophagectomy. This study aims to achieve international consensus using Delphi methodology. The expert panel consisted of 40 esophageal surgeons spanning 16 countries and 4 continents. During a 3-round, web-based Delphi process, experts voted for discharge criteria using 5-point Likert scales. Data were analyzed using descriptive statistics. Consensus was reached if agreement was >= 75% in round 3. Consensus was achieved for the following basic criteria: nutritional requirements are met by oral intake of at least liquids with optional supplementary nutrition via jejunal feeding tube. The patient should have passed flatus and does not require oxygen during mobilization or at rest. Central venous catheters should be removed. Adequate analgesia at rest and during mobilization is achieved using both oral opioid and non-opioid analgesics. All vital signs should be normal unless abnormal preoperatively. Inflammatory parameters should be trending down and close to normal (leucocyte count <= 12G/l and C-reactive protein <= 80 mg/dl). This multinational Delphi survey represents the first expert-led process for consensus criteria to determine 'fit-for-discharge' status after esophagectomy. Results of this Delphi survey may be applied to clinical outcomes research as an objective measure of short-term recovery. Furthermore, standardized endpoints identified through this process may be used in clinical practice to guide decisions regarding patient discharge and may help to reduce the risk of premature discharge or prolonged admission.
- Published
- 2021
43. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer
- Author
-
Thomas, M., Mortensen, H., Hoffmann, L., Møller, D., (0000-0001-9550-9050) Troost, E. G. C., Muijs, C., Berbee, M., Bütof, R., Nicholas, O., Radhakrishna, G., Defraene, G., Nafteux, P., Nordsmark, M., Haustermans, K., Thomas, M., Mortensen, H., Hoffmann, L., Møller, D., (0000-0001-9550-9050) Troost, E. G. C., Muijs, C., Berbee, M., Bütof, R., Nicholas, O., Radhakrishna, G., Defraene, G., Nafteux, P., Nordsmark, M., and Haustermans, K.
- Abstract
Purpose To define instructions for delineation of target volumes in the neoadjuvant setting in oesophageal cancer. Materials and methods Radiation oncologists of five European centres participated in the following consensus process: [1] revision of published (MEDLINE) and national/institutional delineation guidelines; [2] first delineation round of five cases (patient 1–5) according to national/institutional guidelines; [3] consensus meeting to discuss the results of step 1 and 2, followed by a target volume delineation proposal; [4] circulation of proposed instructions for target volume delineation and atlas for feedback; [5] second delineation round of five new cases (patient 6–10) to peer review and validate (two additional centres) the agreed delineation guidelines and atlas; [6] final consensus on the delineation guidelines depicted in an atlas. Target volumes of the delineation rounds were compared between centres by Dice similarity coefficient (DSC) and maximum/mean undirected Hausdorff distances (Hmax/Hmean). Results In the first delineation round, the consistency between centres was moderate (CTVtotal: DSC = 0.59–0.88; Hmean = 0.2–0.4 cm). Delineations in the second round were much more consistent. Lowest variability was obtained between centres participating in the consensus meeting (CTVtotal: DSC: p < 0.050 between rounds for patients 6/7/8/10; Hmean: p < 0.050 for patients 7/8/10), compared to validation centres (CTVtotal: DSC: p < 0.050 between validation and consensus meeting centres for patients 6/7/8; Hmean: p < 0.050 for patients 7/10). A proposal for delineation of target volumes and an atlas were generated. Conclusion We proposed instructions for target volume delineation and an atlas for the neoadjuvant radiation treatment in oesophageal cancer. These will enable a more uniform delineation of patients in clinical practice and clinical trials.
- Published
- 2021
44. Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus
- Author
-
MS CGO, Cancer, Müller, P. C., Kapp, J. R., Vetter, D., Bonavina, L., Brown, W., Castro, S., Cheong, E., Darling, G. E., Egberts, J., Ferri, L., Gisbertz, S. S., Gockel, I., Grimminger, P. P., Hofstetter, W. L., Hölscher, A. H., Low, D. E., Luyer, M., Markar, S. R., Mönig, S. P., Moorthy, K., Morse, C. R., Müller-Stich, B. P., Nafteux, P., Nieponice, A., Nieuwenhuijzen, G. A.P., Nilsson, M., Palanivelu, C., Pattyn, P., Pera, M., Räsänen, J., Ribeiro, U., Rosman, C., Schröder, W., Sgromo, B., Van Berge Henegouwen, M. I., Van Hillegersberg, R., Van Veer, H., Van Workum, F., Watson, D. I., Wijnhoven, B. P.L., Gutschow, C. A., MS CGO, Cancer, Müller, P. C., Kapp, J. R., Vetter, D., Bonavina, L., Brown, W., Castro, S., Cheong, E., Darling, G. E., Egberts, J., Ferri, L., Gisbertz, S. S., Gockel, I., Grimminger, P. P., Hofstetter, W. L., Hölscher, A. H., Low, D. E., Luyer, M., Markar, S. R., Mönig, S. P., Moorthy, K., Morse, C. R., Müller-Stich, B. P., Nafteux, P., Nieponice, A., Nieuwenhuijzen, G. A.P., Nilsson, M., Palanivelu, C., Pattyn, P., Pera, M., Räsänen, J., Ribeiro, U., Rosman, C., Schröder, W., Sgromo, B., Van Berge Henegouwen, M. I., Van Hillegersberg, R., Van Veer, H., Van Workum, F., Watson, D. I., Wijnhoven, B. P.L., and Gutschow, C. A.
- Published
- 2021
45. Endoscopic thoracic sympathectomy for posttraumatic complex regional pain syndrome
- Author
-
Demey, K., Nijs, S., Coosemans, W., Decaluwé, H., Decker, G., De Leyn, P., Van Raemdonck, D., Sermon, A., Broos, P., Lerut, T., and Nafteux, P.
- Published
- 2011
- Full Text
- View/download PDF
46. Oesophageal perforation after anterior cervical surgery: management in four patients
- Author
-
Ardon, H., Van Calenbergh, F., Van Raemdonck, D., Nafteux, P., Depreitere, B., van Loon, J., and Goffin, J.
- Published
- 2009
- Full Text
- View/download PDF
47. Outcomes of different treatment approaches after R0 endoscopic resection of high-risk T1 esophageal adenocarcinoma: An international multicentre retrospective cohort study.
- Author
-
Chan, M. W., Haidry, R., Benjamin, N., Di Pietro, M., Hadjinicolaou, A. V., Barret, M., Doumbe-Mandengue, P., Seewald, S., Bisschops, R., Nafteux, P., Bourke, M. J., Gupta, S., Mundre, P., Lemmers, A., Vuckovic, C., Pech, O., Leclercq, P., Coron, E., Meijer, S., and Bergman, J.
- Subjects
ENDOSCOPIC surgery ,COHORT analysis ,ADENOCARCINOMA ,RETROSPECTIVE studies - Abstract
This article discusses the outcomes of different treatment approaches after R0 endoscopic resection (ER) of high-risk T1 esophageal adenocarcinoma (EAC). The study aimed to assess the outcomes following R0 ER for high-risk T1 EAC, specifically looking at the risk of lymph node metastases (N+). The study found that the majority of cases with surgical T1 had ER misclassified as R0, challenging previous studies that reported higher N+ rates. The results suggest that surgery is not a definitive curative approach and did not improve disease-specific mortality. Further research is needed to evaluate outcomes in patients treated endoscopically for high-risk T1 EAC. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
48. Laparoscopic Nissen fundoplication in infants and children: analysis of 106 consecutive patients with special emphasis in neurologically impaired vs. neurologically normal patients
- Author
-
Mathei, Jan, Coosemans, Willy, Nafteux, Philippe, Decker, George, De Leyn, Paul, Van Raemdonck, Dirk, Hoffman, Ilse, Deboeck, Christiane, Proesmans, Marijke, and Lerut, Toni
- Published
- 2008
- Full Text
- View/download PDF
49. Impact of the introduction of an enhanced recovery pathway in esophageal cancer surgery: a cohort study and propensity score matching analysis
- Author
-
Moons, J, primary, Depypere, L, additional, Lerut, T, additional, van Achterberg, T, additional, Coosemans, W, additional, Van Veer, H, additional, Mandeville, Y, additional, and Nafteux, P, additional
- Published
- 2021
- Full Text
- View/download PDF
50. Diagnostic criteria and symptom grading for delayed gastric conduit emptying after esophagectomy for cancer: international expert consensus based on a modified Delphi process
- Author
-
Konradsson, M., Berge Henegouwen, M.I. van, Bruns, C., Chaudry, M.A., Cheong, E., Cuesta, M.A., Darling, G.E., Gisbertz, S.S., Griffin, S.M., Gutschow, C.A., Hillegersberg, R. van, Hofstetter, W., Hölscher, A.H., Kitagawa, Y., Lanschot, J.Jan B. van, Lindblad, M., Ferri, L.E., Low, D.E., Luyer, M.D., Ndegwa, N., Mercer, S., Moorthy, K., Morse, C.R., Nafteux, P., Nieuwehuijzen, G.A.P., Pattyn, P., Rosman, C., Ruurda, J.P., Räsänen, J., Schneider, P.M., Schröder, W., Sgromo, B., Veer, H. van der, Wijnhoven, B.P., Nilsson, M., Konradsson, M., Berge Henegouwen, M.I. van, Bruns, C., Chaudry, M.A., Cheong, E., Cuesta, M.A., Darling, G.E., Gisbertz, S.S., Griffin, S.M., Gutschow, C.A., Hillegersberg, R. van, Hofstetter, W., Hölscher, A.H., Kitagawa, Y., Lanschot, J.Jan B. van, Lindblad, M., Ferri, L.E., Low, D.E., Luyer, M.D., Ndegwa, N., Mercer, S., Moorthy, K., Morse, C.R., Nafteux, P., Nieuwehuijzen, G.A.P., Pattyn, P., Rosman, C., Ruurda, J.P., Räsänen, J., Schneider, P.M., Schröder, W., Sgromo, B., Veer, H. van der, Wijnhoven, B.P., and Nilsson, M.
- Abstract
Contains fulltext : 225948.pdf (Publisher’s version ) (Open Access), Delayed gastric conduit emptying (DGCE) after esophagectomy for cancer is associated with adverse outcomes and troubling symptoms. Widely accepted diagnostic criteria and a symptom grading tool for DGCE are missing. This hampers the interpretation and comparison of studies. A modified Delphi process, using repeated web-based questionnaires, combined with live interim group discussions was conducted by 33 experts within the field, from Europe, North America, and Asia. DGCE was divided into early DGCE if present within 14 days of surgery and late if present later than 14 days after surgery. The final criteria for early DGCE, accepted by 25 of 27 (93%) experts, were as follows: >500 mL diurnal nasogastric tube output measured on the morning of postoperative day 5 or later or >100% increased gastric tube width on frontal chest x-ray projection together with the presence of an air-fluid level. The final criteria for late DGCE accepted by 89% of the experts were as follows: the patient should have 'quite a bit' or 'very much' of at least two of the following symptoms; early satiety/fullness, vomiting, nausea, regurgitation or inability to meet caloric need by oral intake and delayed contrast passage on upper gastrointestinal water-soluble contrast radiogram or on timed barium swallow. A symptom grading tool for late DGCE was constructed grading each symptom as: 'not at all', 'a little', 'quite a bit', or 'very much', generating 0, 1, 2, or 3 points, respectively. For the five symptoms retained in the diagnostic criteria for late DGCE, the minimum score would be 0, and the maximum score would be 15. The final symptom grading tool for late DGCE was accepted by 27 of 31 (87%) experts. For the first time, diagnostic criteria for early and late DGCE and a symptom grading tool for late DGCE are available, based on an international expert consensus process.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.